Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Insomnia and clinical pain in sickle cell disease patients
source: The Journal of Pain
year: 2017
authors: A. Tilton, P. Carroll, S. Lanzkron, K. Kiley, M. Smith, J. Smythe, J. Haythornthwaite, C. Campbell
summary/abstract:Chronic pain is one of several debilitating complications that arises in patients suffering from sickle cell disease with many patients reporting concurrent sleep disturbance. It is widely recognized that pain disrupts sleep, however little is known about how sleep affects pain in this population. The current analyses examined SCD patients’ calculated Insomnia Severity Index (ISI) scores and its prospective relationship to self-reported clinical pain over a 90 day electronic diary period, 3 months of weekly telephone calls, and one year of monthly telephone calls. Seventy-two African American SCD patients rated their average daily clinical pain (x=26.60/100, SD=20.84) and 64 of them remained in the study and completed the weekly and monthly calls (average clinical pain x=2.5/10, SD=1.7 and x=3.5/10, SD=1.9, respectively). Multivariate models predicting clinical pain at each time period controlled for education, sex, age, central sensitization (CS), depression, and chronic opioid therapy (COT). ISI independently predicted 7.5 % of the variance in clinical pain during the diary period. The overall model accounted for 76% of the total variance, with COT, CS, and ISI significant covariates in the model. ISI independently predicted 7.6% of the variance in clinical pain over the 3 months of weekly calls. Both COT and ISI were significant in this model, for which 65% of the total variance was accounted. Lastly, in the twelve month period of monthly calls, ISI independently predicted 9.2% of the variance in clinical pain during the final 12 months of observation, accounting for 66% of the variance. COT, ISI, and depression were significant for this final model. These data suggest that sleep has a significant and long-lasting influence on SCD pain and deserves further, in-depth investigation.
organization: Johns Hopkins University School of Medicine, Baltimore, MDDOI: 10.1016/j.jpain.2017.02.159
read more
Related Content
-
Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysisThe cell adhesion molecule P-selectin pl...
-
Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Si...BACKGROUND: Sickle cell disease (SCD) is...
-
Johns Hopkins researchers offer new protocol to potentially cure sickle cell diseaseThere's new hope for patients who have b...
-
North Star Reach Summer “Camp-At-Home” – Sickle Cell/Hematology/Pain Management CampAlthough we are not gathering at North S...
-
The Cellie Coping Kit helps sick kids manage the stress of treatmentDesigned by Marsac during her fellowship...
-
Simon Dyson, PhDSimon Dyson is Professor of Applied Soci...
-
Town Hall Meeting: A policy discussion on the challenges facing the sickle cell communityHemoglobinopathies (Sickle Cell ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.